An Open Label, Non-Randomized Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066 After Oral Administration to Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2010
At a glance
- Drugs AZD 2066 (Primary)
- Indications Gastro-oesophageal reflux; Neuropathic pain
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 09 Dec 2010 Actual end date changed from Jul 2008 to Jun 2008 as reported by ClinicalTrials.gov.
- 18 Jun 2008 New trial record.